DOI: 10.25881/BPNMSC.2020.29.19.029

Authors

Butareva D.V., Hanaliev B.V., Daminov V.D.

Pirogov National Medical and Surgical Center, Moscow

Abstract

This article provides a review of the literature on the use of botulinum toxin type A in urological practice, the definition of indications, contraindications to this type of treatment and methods of administration of this drug. The most common conservative treatment for an overactive bladder is the administration of anticholinergic drugs, but sometimes the effect of M-holinoblockers is either insufficient or poorly tolerated due to a large number of adverse reactions. According to the literature, lower urinary tract dysfunction occurs in 17% of the population and can lead to chronic kidney disease and reduce the quality of life. One of the fundamentally new directions among the methods of treatment overactive bladder of various etiologies is the introduction of botulinum toxin type A into the muscle layer of the bladder wall, which has shown good results.

Keywords: urology, neurourology, botulinum toxin A, urinary incontinence, imperative urges, overactive bladder, urinary tract syndrome, painful bladder syndrome, interstitial cystitis, intravesical administration, detrusor, comprehensive urodynamic study.

References

1. Vasiliev AV, Shumilo DV, Tur EI. Botulinoterapia u bolnykh neirogennoi detruzornoi giperaktivnostyu refrakternoi k antiholinergicheskoi terapii. In: (Conference proceedings) Neiroreabilitatsiya 2010. Moscow; 2010. P. 114–115.

2. Krivoborodov GG, Vasiliev AV, Shumilo DV, et al. Botulinum toxin type A in patients with overactive bladder. Urologiya. 2010;(3):36–40.

3. Gadzhieva ZK. Narusheniya mocheispuskania. Ed by Yu.G. Alyaev. Moscow: GEOTAR-Media; 2010. 176 p.

4. Kasyan GR, Kupriyanov YuA, Lysachev DA, Sadchenko AV. Metodicheskie recomendatsii №25. Botulinoterapiya v urologii. Moscow; 2020.

5. Krivoborodov GG, Vasiliev AV, Shumilo DV, et al. Botulinum toxin type A in patients with overactive bladder. Urologiya. 2010;(3):36–40.

6. Pushkar DYu, Kasyan GR. Funktsional'naya urologiya i urodinamika. Moscow: GEOTAR-Media; 2013. 375 p.

7. Abrams P. Urodynamics. 3rd ed. London: Springer; 2005. 339 p.

8. Alavinia SM, Omidvar M, Farahani F, et al. Enhancing quality practice for prevention and diagnosis of urinary tract infection during inpatient spinal cord rehabilitation. J Spinal Cord Med. 2017;40(6):803–812. doi: 10.1080/10790268.2017.1369216.

9. auanet.org [Internet]. American Association of Urology. Diagnosis and Treatment Algorithm: AUA/SUFU Guideline on Neurogenic Overactive Bladder in Adults [cited 2020 Jul 12].

10. Ammirati E, Manassero A, Giammò A, Carone R. Management of male and female neurogenic stress urinary incontinence in spinal cord injured (SCI) patients using adjustable continence therapy. Urologia. 2017;84(3):165–168. doi: 10.5301/uj.5000242.

11. Bottet F, Peyronnet B, Boissier R, et al. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of onabotulinum toxin A failed. Neurourol Urodyn. 2018;37(1):291–297. doi: 10.1002/nau.23291.

12. Cameron AP, Clemens JQ, Latini JM, McGuire EJ. Combination drug therapy improves compliance of the neurogenic bladder. J Urol. 2009;182(3):1062–1067. doi: 10.1016/j.juro.2009.05.038.

13. Chapple CR, MacDiarmid SA, Patel A. Urodynamics Made Easy. Elsevier Health Sciences; 2009. 232 p.

14. Datta SN, Roosen A, Pullen A, et al. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration. J Urol. 2010;184(6):2578–2585. doi: 10.1016/j.juro.2010.07.034.

15. Del Popolo G, Filocamo MT, Li Marzi V, et al. Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. Eur Urol. 2008;53(5):1013–1019. doi: 10.1016/j.eururo.2007.09.034.

16. uroweb.org [Internet]. European Association of Urology. Guidelines on Urinary Incontinence. 2014. P. 102–103 [cited 2020 Jul 12].

17. Furusawa K, Tokuhiro A, Sugiyama H, et al. Incidence of symptomatic autonomic dysreflexia varies according to the bowel and bladder management techniques in patients with spinal cord injury. Spinal Cord. 2011;49(1):49–54. doi: 10.1038/sc.2010.94.

18. Giannantoni A, Di Stasi SM, Stephen RL, et al. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol. 2004;172(1):240–243. doi: 10.1097/01.ju.0000132152.53532.5d.

19. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of on a botulinumtoxin A for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131–2139. doi: 10.1016/j.juro.2012.01.125.

20. Guralnick ML, Grimsby G, Liss M, et al. Objective differences between overactive bladder patients with and without urodynamically proven detrusor overactivity. Int Urogynecol J. 2010;21(3):325–329. doi: 10.1007/s00192-009-1030-7.

21. nice.org.uk [Internet]. Urinary incontinence in neurological disease: assessment and management. NICE Clinical Guideline; 2012 [cited 2020 Jul 12].

22. Huang M, Chen H, Jiang C, et al. Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia. J Rehab Med. 2016;48(8):683–687. doi: 10.2340/16501977-2132.

23. Jia C, Liao LM, Chen G, Sui Y. Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury. Spinal Cord. 2013;51(6):487–490. doi: 10.1038/sc.2012.180.

24. Koschorke M, Leitner L, Sadri H, et al. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment? BJU Int. 2017;120(6):848–854. doi: 10.1111/bju.13976.

25. Krhut J, Borovička V, Bílková K, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity - prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2018;37(7):2226–2233. doi: 10.1002/nau.23566.

26. Madersbacher H, Mürtz G, Stöhrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord. 2013;51(6):432–441. doi: 10.1038/sc.2013.19.

27. Mitsui T, Minami K, Furuno T, et al. Is suprapubic cystostomy an optimal urinary management in high quadriplegics?. A comparative study of suprapubic cystostomy and clean intermittent catheterization. Eur Urol. 2000;38(4):434–438. doi: 10.1159/000020320.

28. Ni J, Wang X, Cao N, et al. Is repeat Botulinum Toxin A injection valuable for neurogenic detrusor overactivity - a systematic review and meta-analysis. Neurourol Urodyn. 2018;37(2):542–553. doi: 10.1002/nau.23354.

29. Nitti VW, Dmochowski R, Herschorn S, et al. On a botulinum toxin A for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo-controlled trial. J Urol. 2013;189(6):2186–2193. doi: 10.1016/j.juro.2012.12.022.

30. Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 2015;14(7):720–732. doi: 10.1016/S1474-4422(15)00070-8.

31. Reitz A, Stöhrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004;45(4):510–515. doi: 10.1016/j.eururo.2003.12.004.

32. Rovner E, Kohan A, Chartier-Kastler E, et al. Long term efficacy and safety of onabotulinumtoxina in patients with neurogenic detrusor overactivity who completed 4 years of treatment. J Urol. 2016;196(3):801–808. doi: 10.1016/j.juro.2016.04.046.

33. Schurch B, de Sèze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo-controlled 6-month study. J Urol. 2005;174(1):196–200. doi: 10.1097/01.ju.0000162035.73977.1c.

34. Tyagi P, Kashyap M, Yoshimura N, et al. Past, present and future of chemodenervation with botulinum toxin in the treatment of overactive bladder. J Urol. 2017;197(4):982–990. doi: 10.1016/j.juro.2016.11.092.

35. van Rey F, Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol. 2011;2011:834753. doi: 10.1155/2011/834753.

36. Wagle Shukla A, Malaty IA. Botulinum toxin therapy for Parkinson’s disease. Semin Neurol. 2017;37(2):193–204. doi: 10.1055/s-0037-1602246.

37. Weld KJ, Dmochowski RR. Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology. 2000;55(4):490–494. doi: 10.1016/s0090-4295(99)00553-1.

For citation

Butareva D.V., Hanaliev B.V., Daminov V.D. Use of botulinum toxin type A in urological practice. Bulletin of Pirogov National Medical & Surgical Center. 2020;3-2(15):166-171. (In Russ.) https://doi.org/10.25881/BPNMSC.2020.29.19.029